10-Q: XOMA Royalty Corporation Reports Second Quarter 2024 Results, Including Kinnate Acquisition
Quarterly Report
XOMA Royalty Corporation reports a net income of $16.0 million for the second quarter of 2024, driven by the acquisition of Kinnate and changes in fair value of assets.
Summary
- XOMA Royalty Corporation reported a net income of $16.0 million for the three months ended June 30, 2024, and $7.4 million for the six months ended June 30, 2024.
- The company's revenue for the quarter was $11.1 million, including $5.4 million from purchased receivables and $5.0 million from contracts with customers.
- Operating expenses totaled $21.2 million for the quarter, including a $9.0 million impairment of a royalty purchase agreement asset.
- The company recognized a gain of $19.3 million from the acquisition of Kinnate.
- XOMA's cash, cash equivalents, and restricted cash totaled $149.9 million as of June 30, 2024.
- The company used $2.2 million in operating activities and $1.4 million in investing activities for the six months ended June 30, 2024.
- XOMA has a stock repurchase program that permits the company to purchase up to $50.0 million of its common stock through January 2027.
Sentiment
Score: 7
Explanation: The document shows a positive financial performance with a significant net income and gains from acquisitions. However, there are also some negative aspects such as high operating expenses and an impairment charge. Overall, the sentiment is positive but with some caution.
Positives
- The company achieved a significant net income of $16.0 million for the quarter.
- The Kinnate acquisition resulted in a substantial gain of $19.3 million.
- The company recognized a $5.0 million milestone payment from Rezolute.
- The company recognized a $8.1 million gain from a change in fair value of an embedded derivative related to a royalty purchase agreement.
- The company has a strong cash position of $149.9 million.
Negatives
- Operating expenses were high at $21.2 million for the quarter.
- The company recorded a $9.0 million impairment of a royalty purchase agreement asset related to Aronora.
- The company used $2.2 million in operating activities and $1.4 million in investing activities for the six months ended June 30, 2024.
Risks
- The company's future revenue is dependent on the success of its licensees and their products.
- Changes in expected cash flows for royalty and commercial receivables can result in material adjustments to income.
- The company's amortization of the Blue Owl Loan is dependent on commercial payments from Roche, which can result in material adjustments to interest expense and term loan balance.
- The company's estimates of future cash flows are subject to change based on various factors, including research analyst coverage, commercial performance of products, and contract or patent duration.
- The company's financial condition is dependent on its ability to fund its planned operations and commitments.
Future Outlook
The company expects most of its future revenue to be based on milestone payments and royalties associated with its acquired programs. The company also expects G&A expenses for the full year of 2024 to be higher than G&A expenses in 2023 due to additional costs associated with the Kinnate acquisition and anticipated activity related to potential royalty or other acquisitions.
Industry Context
The company operates in the biotech royalty aggregator space, which involves acquiring rights to future milestone and royalty payments. This model is focused on early to mid-stage clinical assets with significant commercial potential, often licensed to large-cap partners. The company also acquires revenue streams on late-stage or commercial assets that address unmet markets or have a therapeutic advantage.
Comparison to Industry Standards
- The company's focus on acquiring royalty and milestone streams from partnered commercial and pre-commercial therapeutic candidates is a common strategy in the biotech royalty aggregation industry.
- The company's approach of targeting early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential is similar to other royalty aggregators.
- The company's acquisition of Kinnate and its associated assets is a significant event that is likely to impact its future financial performance.
- The company's use of the effective interest rate method for accounting for rights to future milestones, royalties, and commercial payments is a standard practice in the industry.
- The company's impairment of the Aronora royalty purchase agreement asset is a reminder of the risks associated with investing in early-stage assets.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Owen Hughes (Interim) | Owen Hughes | 2024-01-01 | Appointment to full-time Chief Executive Officer |
Stakeholder Impact
- Shareholders will benefit from the positive financial results and the potential for future growth.
- Employees may benefit from the company's continued success and growth.
- Customers of the company's licensees may benefit from the development and commercialization of new therapies.
- Suppliers and creditors may benefit from the company's strong financial position.
Next Steps
- The company will continue to evaluate potential royalty or other acquisitions.
- The company will continue to monitor the performance of its existing portfolio of assets.
- The company will continue to manage its cash flow and expenses.
Key Dates
| Date | Description |
|---|---|
| 2006-11-01 | Date of the Takeda Collaboration Agreement. |
| 2015-09-30 | Date of the Anti-TGF Antibody License Agreement with Novartis. |
| 2016-12-21 | Date of the Royalty Sale Agreements with HCRP. |
| 2017-08-24 | Date of the Gevokizumab License Agreement with Novartis. |
| 2017-12-06 | Date of the license agreement with Rezolute. |
| 2018-09-20 | Date of the Agenus Royalty Purchase Agreement. |
| 2019-04-07 | Date of the Aronora Royalty Purchase Agreement. |
| 2019-08-01 | Date of the agreement with Janssen. |
| 2019-09-26 | Date of the Palo Royalty Purchase Agreement. |
| 2021-03-22 | Date of the Viracta Royalty Purchase Agreement. |
| 2021-07-14 | Date of the Kuros Royalty Purchase Agreement. |
| 2021-10-06 | Date of the Affitech Commercial Payment Purchase Agreement. |
| 2023-03-29 | Date of the Aptevo Commercial Payment Purchase Agreement. |
| 2023-06-21 | Date of the LadRx Agreements. |
| 2023-12-15 | Date of the Blue Owl Loan Agreement. |
| 2024-01-12 | Date of the Talphera Commercial Payment Purchase Agreement. |
| 2024-02-16 | Date of the Kinnate Merger Agreement. |
| 2024-02-27 | Date of the Exarafenib Sale by Kinnate. |
| 2024-04-03 | Date of the Kinnate Merger Closing Date. |
| 2024-04-29 | Date of the Dar Royalty Purchase Agreements. |
| 2024-05-30 | Date of the Viracta Priority Review Voucher sale. |
| 2024-06-03 | Date of the amendment to the LadRx RPA. |
| 2024-06-30 | End of the reporting period. |
| 2024-07-10 | Date of the name change to XOMA Royalty Corporation. |
Keywords
royalty aggregator, milestone payments, royalty payments, Kinnate acquisition, VABYSMO, Rezolute, financial results, biotech, pharmaceuticals, commercial payments
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.